![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, August 06, 2019 6:08:19 AM
Download as PDFAugust 06, 2019 6:00am EDT
VANCOUVER, Washington, Aug. 06, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the injection of the first patient with metastatic triple-negative breast cancer (“mTNBC”). The patient will be treated with leronlimab by Jacob Lalezari, M.D., currently Chief Executive Officer of Quest Clinical Research. Dr. Lalezari is also a principal investigator in CytoDyn’s HIV clinical trials with leronlimab.
“This patient has a particularly aggressive type of mTNBC and is being treated under emergency IND regulations of the FDA,” stated Dr. Lalezari. “With the exciting preclinical studies in cancer metastasis completed by the Company, I believe that leronlimab represents a new potentially therapeutic modality in mTNBC.” Dr. Lalezari has authored more than 75 peer-reviewed articles and been a principal investigator in over 200 clinical trials with a particular focus on first-in-man and proof of concept studies.
The use of leronlimab for mTNBC under the emergency IND by Dr. Lalezari is in addition to the Phase 1b/2 trial with leronlimab for treatment-naïve mTNBC patients under the supervision of Massimo Cristofanilli, M.D., who is an expert in translational research treatment of patients with mTNBC and professor of Medicine in the Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine. Results from the Phase 1b/2 trial for mTNBC will dictate the Company’s regulatory pathway, including the potential to seek Breakthrough Therapy Designation and accelerated approval with the U.S. Food and Drug Administration (“FDA”) for the use of leronlimab in mTNBC. Leronlimab has been granted Fast Track designation for mTNBC by the FDA based on a greater than 98% reduction of metastatic tumor volume in a murine xenograft model.
“Today marks a milestone in our Company’s history, a first step into the oncology space,” stated CytoDyn President and CEO, Nader Pourhassan, Ph.D. “It is equally important to note that leronlimab has already completed eight successful clinical trials and has been dosed in over 800 patients in our HIV programs, without any drug-related serious adverse events (SAEs),” he continued. “With results from multiple preclinical studies in various cancer indications, including mTNBC, we are optimistic about the potential of leronlimab to provide a new therapeutic option to many patients.”
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM